Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,556.37
(
0.00%
)
US TECH 100
23,590.00
(
0.99%
)
Dow Jones
46,124.06
(
0.00%
)
Brent Oil
95.60
(
-0.94%
)
Bitcoin
71,668.18
(
1.63%
)
News Focus
News Focus
Post# of 257275
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122807
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: oc631 post# 137214

Friday, 02/17/2012 11:05:43 AM

Friday, February 17, 2012 11:05:43 AM

Post# of 257275

GILD—GS-7977 gets straight A's for efficacy, tolerability, and safety but now the strength of the drug’s resistance profile when used orally in combination with ribavirin is in question.

It’s a little early to say that the resistance profile per se is the main culprit in the data reported today. This was asked and answered on the CC.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today